Followers | 14 |
Posts | 1,650 |
Boards Moderated | 0 |
Alias Born | 11/01/2010 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not as much as the rest of the regular posters are holding. We'll see. We had a big run a while ago off of rumors.
This thing trades off of PFM so whoever is short might not need the luck. Especially when you consider the consistent nothing we get from the company but patience may pay off. I'm looking to exit at or above .21
Yeah, I used to pay all those fees with Sharebuilder. I tried to move all of my account to Etrade but they wouldn't take some of it. It's now Captial One Investing and Etrade bought them out so I wonder how this will work. I still own shares in companies worth basically nothing.
https://www.fool.com/investing/2018/01/29/why-your-capital-one-investing-brokerage-account-i.aspx
Past two weeks have been rough. Did one of the cheerleaders jump ship? Is everyone accounted for?
Sounds like someone jumped ship
Maybe with talk of 80% margins we can afford to do this temporarily?
Did anyone get a chance to hear the conference call? I was late but tried both the call and the replay.
edit: just tried and the replay is no longer available
I've been holding bags since 2016 so your words don't mean much. Hopefully you keep.the same energy if we are still here or lower this time next year. They say you don't lose until you sell but that's not always true.
Sounds reasonable. I definitely do see it happening soon.
I guess will be waiting another couple months or until the end of the year. Profit may be the only thing to move us up.
I figure I missed the call but I can't hear the replay either
I ended up trying FlutiCare and it has been working
Innovus Pharmaceuticals Reports Record Quarterly Revenue for the First Quarter 2018 of $4.5 million, Beating Previous Estimate and Net Loss Decrease of 28% Compared to the Same Quarterly Period in 2017
Quarterly Net Revenue Increase of 109% When Compared to the First Quarter of 2017
Innovus Pharmaceuticals, Inc., (“Innovus Pharma” or the “Company”) (OTCQB: INNV), today announced first quarter 2018 net revenue of $4.5 million compared to $2.2 million in net revenue for the same period in 2017.
“We are delighted with our first quarter net revenues of $4.5 million, which beat our previously announced first quarter expectations,” stated Bassam Damaj, President and Chief Executive Officer of Innovus Pharma. “We are very confident in our business strategy and in our ability to grow our sales revenue through our continuously expanding and proprietary Beyond Human™ sales and marketing channels and to develop new products that satisfy the needs of our growing customer base. With a strong cash position of close to $5 million in cash at the end of the first quarter, we are committed and aggressively working towards our goal of profitability as we continue to strengthen and advance our pipeline, which is as strong as it's ever been and expand the sales channels of our Beyond Human™ sales and marketing platform both in the US and abroad,” continued Dr. Damaj.
Financial highlights for the three months ended March 31, 2018 included:
Net revenues totaled $4.5 million for the three months ended March 31, 2018 compared to net revenues of $2.2 million for the three months ended December 31, 2016 representing a 108.7% increase.
Sequential quarter over quarter revenue increase of 91.0% in the first quarter 2018 compared to an increase of 28.7% in the first quarter 2017.
Gross margins increased to 81% for the three months ended March 31, 2018 compared to 80% the same three-month period in 2017.
Total cash on hand close to $5 million at March 31, 2018
Total non-product operating expenses increased to $5.0 million and included $0.1 million in non-cash share-based compensation, 0.5 million of non-cash debt related expense, and 0.2 million in non-cash depreciation and amortization for the three months ended March 31, 2018.
Loss from operations decreased to $1.3 million during the three months ended March 31, 2018 compared to $1.7 million during the three months ended March 31, 2017 representing a 19.9% decrease.
Net loss totaled $1.8 million, or $0.01 per common share, for the three months ended March 31, 2018 compared to $2.5 million, or $0.02 per common share, for the three months ended March 31, 2017 representing a decrease of 28.2%. The net loss in 2018 included a non-cash expense of $0.3 million for the loss on debt extinguishment. The net loss also included interest expense of $0.2 million which was non-cash and related to amortization of debt discounts.
First quarter 2018 and recent developments:
Received net cash proceeds of $2.8 million from the exercise of warrants to purchase shares of the Company’s common stock, raised net cash proceeds of $1.9 million from the issuance of notes payable during the first quarter of 2018 and current total cash on hand is $4.9 million;
Entered into an exclusive license and distribution agreement with Acerus Pharmaceuticals in January 2018 granting them exclusive rights to market and sell UriVarx® in Canada;
Entered into an exclusive license and distribution agreement with Lavasta Pharma in January 2018 granting them exclusive rights to market and sell ProstaGorx® in various countries in the Middle East and North Africa;
Launched seven new products;
Received multiple product approvals in Canada; and
Expanded our Beyond Human™ sales and marketing platform to Canada and launched three products there.
The Company will host a conference call at 4:15 p.m. ET/1:15 p.m. PT today to discuss the financial results and recent business developments. To participate in the call, please dial 1-877-883-0383 for domestic callers or 1-412-902-6506 for international callers. Participant Elite Entry Number: 9576665. A replay of the call will be available for 30 days. To access the replay, dial 1-877-344-7529 domestically or 1-412-317-0088 internationally and reference Conference ID: 10118224. The replay will be available shortly after the end of the conference call.
Consolidated Statements of Operations
Three months ended
March 31,
2018 2017
(unaudited)
Net revenue:
Product sales, net $4,542,026 $2,177,290
License revenue 2,578 -
Total net revenue 4,544,604 2,177,290
Operating expense:
Cost of product sales 864,095 440,476
Research and development 11,287 3,183
Sales and marketing 3,301,784 1,687,351
General and administrative 1,696,021 1,704,663
Total operating expense 5,873,187 3,835,673
Loss from operations (1,328,583 ) (1,658,383 )
Other income and (expense):
Interest expense (241,888 ) (557,479 )
Loss on extinguishment of debt (255,685 ) (304,828 )
Other income (expense), net 109 (616 )
Fair value adjustment for contingent consideration (2,845 ) 27,175
Change in fair value of derivative liabilities - (51,656 )
Total other expense, net (500,309 ) (887,404 )
Net loss (1,828,892 ) (2,545,787 )
Net loss per share of common stock – basic and diluted:
$(0.01
)
$(0.02
)
Weighted average number of shares of common stock outstanding – basic and diluted
186,933,622
135,099,173
Condensed Consolidated Balance Sheet Data
March 31, 2018
1
Assets
Cash $4,923,796
Accounts receivable, net 195,242
Prepaid expenses and other current assets 333,136
Inventories 1,648,730
Intangible assets and other non-current assets
5,292,4661
Total assets $12,393,370
Liabilities & Stockholders' Equity
Accounts payable & accrued liabilities $2,910,282
Total accrued compensation 2,820,113
Deferred revenue and customer deposits 142,769
Accrued interest payable 11,671
Short-term loans payable 32,775 -
Notes payable and non-convertible debenture, net of discount 2,288,876
Total contingent consideration 1,481,848
Total stockholders' equity
2,705,036
Total liabilities & stockholders' equity $12,393,370
1 The Condensed Consolidated Balance Sheet Data has been derived from the audited consolidated financial statements as of that date.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.
For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; www.apeaz.com; and www.diabasens.com.
Innovus Pharma’s Forward-Looking Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, its financial results, projected revenues, projected online subscribers and other customers, estimated markets for its products, and statements about achieving its other corporate and business development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180514005260/en/
Innovus Pharma Investor Relations
Randy Berholtz, +1 858 249 7865
ir@innovuspharma.com
Copyright Business Wire 2018
Source: Business Wire (May 14, 2018 - 4:05 PM EDT)
News by QuoteMedia
www.quotemedia.com
We have to wait for Monday
I use Etrade but haven't purchased additional shares in awhile
big news could be in 2019
I get their press releases to my email. They had a way to sign up for them in the past but it looks like the website has changed or I forgot how to do it. You can try sending a message https://innovuspharma.com/contact-us/
another deadline smh
Just saying I think people are venting
I doubt anyone posting is short. It mostly people that have been holding bags here since Summer 2016 or they took a loss.
I have your same opinion from way back then lol #3108
No more promises. They should just do the work. They are pissing people off unnecessarily.
Every seller requires a buyer
Buying on the bid
Good lord not another deadline that they'll probably miss! Just get it done
Or maybe too much cheerleading on the board. I don't have anything to back this up but I doubt the turnout was good for that recent presentation. I always question turnout when you don't show the crowd or only part of the crowd. Also, there was a lot of other companies presenting so we were competing against them for attention. So then you look at that and the people predicting a spike and i'm not surprised if some new investors walk away.
We should just stick to posting the facts. A lot of good stuff to focus on.
Doesn't mean people will attend. I'm sure with their net worth they can take a conference fee loss. Though I think New York should be able to handle a foot of snow.
So you are telling to consider buying Fluticare after I just said I was considering buying Fluticare. Such a meaningful post.
No the reviews are consistently good. I'm not putting anymore money in the stock but I could probably use their product.
I don't think 2018 forward guidance will have that big of an effect. They have missed in the past. I'm more interested in Q1
The reviews have me curious, since I do have allergies in the spring time
my guess, last years numbers weren't that great but the first quarter 2018 numbers are looking good
Innovus Pharmaceuticals to Release Annual 2017 Financial Results, Preliminary First Quarter 2018 Revenues and Provide Corporate Update on Monday, April 2, 2018
SAN DIEGO
Innovus Pharmaceuticals, Inc., (“Innovus Pharma”) (OTCQB: INNV), today announced that the Company will release its December 31, 2017 annual financial results, its preliminary first quarter 2018 revenues and provide a corporate update on Monday, April 2, 2018, after the close of the U.S. financial markets. The Company will host a conference call at 4:15 p.m. ET/1:15 p.m. PT on the same day to discuss the financial results and recent business developments.
To participate in the call, please dial 1-877-883-0383 for domestic callers or 1-412-902-6506 for international callers or 1-877-885-0477 for Canadian callers and Participant Elite Entry Number: 9576665. A replay of the call will be available for 30 days. To access the replay, dial 1-877-344-7529 domestically or 1-412-317-0088 internationally or 1-855-669-9658 for Canada and reference Conference ID: 10118224. The replay will be available shortly after the end of the conference call.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.
For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; and www.apeaz.com.
Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from its various products, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180316005170/en/
Innovus Pharma Investor Relations
Randy Berholtz, +1 858 249 7865
ir@innovuspharma.com
Copyright Business Wire 2018
Source: Business Wire (March 16, 2018 - 6:00 AM EDT)
News by QuoteMedia
www.quotemedia.com
It is possible. Etrade will let you do it but they charge a large fee
Well the reviews for Fluticare seem to be consistently good
It just where they expect the price to go but it is speculation. They feel confident about the company at the moment.